<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bictegravir, emtricitabine, and tenofovir alafenamide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bictegravir, emtricitabine, and tenofovir alafenamide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bictegravir, emtricitabine, and tenofovir alafenamide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="116731" href="/d/html/116731.html" rel="external">see "Bictegravir, emtricitabine, and tenofovir alafenamide: Drug information"</a> and <a class="drug drug_patient" data-topicid="116882" href="/d/html/116882.html" rel="external">see "Bictegravir, emtricitabine, and tenofovir alafenamide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F51090581"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Post treatment acute exacerbation of hepatitis B:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of bictegravir/emtricitabine/tenofovir alafenamide.</p>
<p style="text-indent:-2em;margin-left:2em;">Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue bictegravir/emtricitabine/tenofovir alafenamide. If appropriate, anti-hepatitis B therapy may be warranted.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F51128447"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Biktarvy</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52872363"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Biktarvy</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F53308045"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiretroviral, Integrase Inhibitor (Anti-HIV)</span>;</li>
<li>
<span class="list-set-name">Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)</span>;</li>
<li>
<span class="list-set-name">Antiretroviral, Reverse Transcriptase Inhibitor, Nucleotide (Anti-HIV)</span></li></ul></div>
<div class="block dop drugH1Div" id="F53334587"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Multiple tablet strengths are available and contain different amounts of each component; use caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment: Note: </b>Gene mutation and antiretroviral resistance patterns should be evaluated (refer to https://www.iasusa.org for more information) when necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight 14 to &lt;25 kg: Bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg per tablet: Oral: One tablet once daily. <b>Note: </b>In clinical trials evaluating this dose, the youngest patients were 3 years of age.</p>
<p style="text-indent:-2em;margin-left:6em;">Weight ≥25 kg: Bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg per tablet: Oral: One tablet once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53334588"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients weighing ≥14 kg:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease on hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling; however, based on data in adults with end-stage renal disease, the standard dose is recommended, with administration after hemodialysis on dialysis days.</p></div>
<div class="block dohp drugH1Div" id="F53334589"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric patients weighing ≥14 kg:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is not recommended (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F51113255"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="116731" href="/d/html/116731.html" rel="external">see "Bictegravir, emtricitabine, and tenofovir alafenamide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Oral: </b>One tablet (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg) once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F51113487"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Kidney impairment prior to treatment initiation</i></b>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Although the manufacturer’s labeling of individual agent emtricitabine suggests adjustments to the dosing interval when CrCl &lt;50 mL/minute, clinical and pharmacokinetic studies suggest that it can be used at usual-recommended doses/intervals when CrCl ≥30 mL/minute; monitor for GI (eg, nausea) and CNS-related adverse effects (Post 2017; Pozniak 2016; Sax 2017b; Valade 2014; expert opinion).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (Sax 2017b; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute: Use not recommended (manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>): </b>Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post-trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Bilbao-Meseguer 2018; Udy 2010).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Dose as for patients with CrCl ≥30 mL/minute (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Bictegravir (no data on dialyzability but not likely removed since &gt;99% protein bound); emtricitabine (~30% removed over 3 hours); tenofovir alafenamide (no data on dialyzability).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral: </b>No dosage adjustment necessary. When a scheduled dose falls on a hemodialysis day, administer after hemodialysis (manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis: Oral:</b> Use not recommended (has not been studied) (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> There are no data available in patients on CRRT (has not been studied). Although some removal of emtricitabine and tenofovir are expected based on physicochemical characteristics, no dosage adjustment is likely necessary (expert opinion).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> There are no data available in patients on CRRT (has not been studied). Although some removal of emtricitabine and tenofovir are expected based on physicochemical characteristics, no dosage adjustment is likely necessary. When a scheduled dose falls on a PIRRT day, administer after PIRRT session (expert opinion).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Nephrotoxicity during treatment:</b></i>Tenofovir alafenamide has been associated with acute kidney injury, proximal tubular nephropathy, and Fanconi syndrome. Although kidney injury is less common with tenofovir alafenamide than tenofovir disoproxil fumarate, discontinue use in patients who develop clinically significant decreases in kidney function or evidence of Fanconi syndrome (Novick 2017; Ueaphongsukkit 2021; manufacturer’s labeling).</p></div>
<div class="block doha drugH1Div" id="F51113488"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustments necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Use is not recommended (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F57150288"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The tenofovir alafenamide fumarate (TAF) component of bictegravir, emtricitabine, tenofovir alafenamide (BIC/FTC/TAF) is associated with kidney impairment, <b>acute kidney injury </b>(AKI), and <b>proximal tubular nephropathy</b>. Cases of TAF-associated AKI and renal tubulopathy (RT) have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35017362','lexi-content-ref-32787843','lexi-content-ref-28885375','lexi-content-ref-30151414','lexi-content-ref-34419091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35017362','lexi-content-ref-32787843','lexi-content-ref-28885375','lexi-content-ref-30151414','lexi-content-ref-34419091'])">Ref</a></span>). Syndromes reported include <b>Fanconi syndrome </b>(FS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32787843']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32787843'])">Ref</a></span>), FS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30690644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30690644'])">Ref</a></span>) and FS with nephrogenic diabetes insipidus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Zhao.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Zhao.2018'])">Ref</a></span>). AKI or RT resolution occurred immediately to 3 months after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30690644','lexi-content-ref-35017362','lexi-content-ref-32787843','lexi-content-ref-34419091','lexi-content-ref-Zhao.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30690644','lexi-content-ref-35017362','lexi-content-ref-32787843','lexi-content-ref-34419091','lexi-content-ref-Zhao.2018'])">Ref</a></span>). Renal function may not return to baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34419091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34419091'])">Ref</a></span>). Incidence is lower than with tenofovir disoproxil fumarate (TDF) in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27765666','lexi-content-ref-HHS.1','lexi-content-ref-33048869']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27765666','lexi-content-ref-HHS.1','lexi-content-ref-33048869'])">Ref</a></span>). TAF has been used safely in patients previously diagnosed with TDF-related FS/RT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31679186','lexi-content-ref-28403627','lexi-content-ref-30224952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31679186','lexi-content-ref-28403627','lexi-content-ref-30224952'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Dose- and time-related; tenofovir inhibition of DNA polymerase-gamma results in mitochondrial DNA (mtDNA) depletion, mitochondrial dysfunction, and cell toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20811330']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20811330'])">Ref</a></span>). Proximal tubule epithelial cells are susceptible due to active uptake of tenofovir by OAT-1 and OAT-3 and efflux by MDRP-4 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27438578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27438578'])">Ref</a></span>). Although TAF is converted to tenofovir in target lymphoid cells and hepatocytes rather than in the plasma like TDF, the proportion of the dose reaching the kidneys is similar. Proximal tubule epithelial cell exposure to tenofovir from TAF is lower than TDF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27438578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27438578'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; onset ranged from 1 day to 9 months, depending on associated risk factors, in reported AKI or RT cases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30690644','lexi-content-ref-35017362','lexi-content-ref-32787843','lexi-content-ref-28885375','lexi-content-ref-30151414','lexi-content-ref-34419091','lexi-content-ref-Zhao.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30690644','lexi-content-ref-35017362','lexi-content-ref-32787843','lexi-content-ref-28885375','lexi-content-ref-30151414','lexi-content-ref-34419091','lexi-content-ref-Zhao.2018'])">Ref</a></span>). In some cases, patients have had prolonged prior use with TDF before initiation of TAF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375','lexi-content-ref-34419091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375','lexi-content-ref-34419091'])">Ref</a></span>). AKI has been described with TDF years after TDF initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32868494','lexi-content-ref-26251709']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32868494','lexi-content-ref-26251709'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent nephrotoxic medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30151414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30151414'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent pharmacologic boosters (eg, cobicistat) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32787843','lexi-content-ref-28885375','lexi-content-ref-33048869','lexi-content-ref-30151414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32787843','lexi-content-ref-28885375','lexi-content-ref-33048869','lexi-content-ref-30151414'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney disease or history of AKI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375','lexi-content-ref-30151414','lexi-content-ref-34419091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375','lexi-content-ref-30151414','lexi-content-ref-34419091'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting liver disease (eg, hepatitis C coinfection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• HIV (especially low CD4 count) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375','lexi-content-ref-30151414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375','lexi-content-ref-30151414'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Previous exposure to TDF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Genetic polymorphisms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28885375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28885375'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) is associated with <b>weight gain</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32504574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32504574'])">Ref</a></span>). Median weight gain 96 weeks after initiation in antiretroviral-naïve individuals was 3.5 kg to 3.6 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31068272','lexi-content-ref-31068270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31068272','lexi-content-ref-31068270'])">Ref</a></span>). Median weight gain at 144 weeks was 4.1 kg to 4.4 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32504574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32504574'])">Ref</a></span>). Weight gain may also plateau (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33148997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33148997'])">Ref</a></span>). Weight increases with BIC/FTC/TAF are not significantly different from those after initiation of dolutegravir (DTG) + abacavir/lamivudine (ABC/3TC) or DTG + FTC/TAF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32504574','lexi-content-ref-31068272','lexi-content-ref-31068270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32504574','lexi-content-ref-31068272','lexi-content-ref-31068270'])">Ref</a></span>), but may be larger than weight increases with darunavir, cobicistat, emtricitabine, tenofovir alafenamide (DRV/COBI/FTC/TAF) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35233432']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35233432'])">Ref</a></span>) or efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33148997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33148997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Switching to an integrase strand inhibitor (INSTI)-containing regimen from EFV/FTC/TDF may be associated with greater weight gain at 18 months than switching to a protease inhibitor (PI)-based regimen or remaining on EFV/FTC/TDF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28825943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28825943'])">Ref</a></span>). Similarly, switching from a TDF to TAF may result in weight gain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30269210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30269210'])">Ref</a></span>). Switching virally suppressed females to ABC/DTG/3TC resulted in greater weight gain than in those remaining on TDF/FTC + nonnucleoside reverse-transcriptase inhibitor (NNRTI) at 48 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32985122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32985122'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">INSTI-containing regimens may be associated with a greater increase in waist circumference in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34888395','lexi-content-ref-32099991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34888395','lexi-content-ref-32099991'])">Ref</a></span>) and patients of black race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32099991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32099991'])">Ref</a></span>). Addition of or switch to an INSTI-containing regimen may be associated with increased risk of metabolic syndrome (including diabetes mellitus) in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31504324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31504324'])">Ref</a></span>) and an increased BMI class (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34877881','lexi-content-ref-33626965','lexi-content-ref-32936919']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34877881','lexi-content-ref-33626965','lexi-content-ref-32936919'])">Ref</a></span>). INSTI-containing regimens may increase risk for obesity compared with non-INSTI-containing regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34888395']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34888395'])">Ref</a></span>). Some data suggest an association between weight gain and cardiovascular disease in INSTI-containing regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35688166']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35688166'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Although there is a case report of a 13 kg/m<sup>2</sup> BMI increase reversing over 2 years with a change from elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide fumarate back to EFV/FTC/TDF (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33176608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33176608'])">Ref</a></span>), it is unclear if this is generalizable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022','lexi-content-ref-33633036','lexi-content-ref-31905383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022','lexi-content-ref-33633036','lexi-content-ref-31905383'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Not clearly established; TAF may have less of a weight suppressive effect than other nucleos(t)ide reverse transcriptase inhibitors (NRTIs). Similarly, INSTIs such as BIC may have less of a weight suppressive effect than other anchor drugs and stimulate weight gain through effects on estrogen-mediated pathways, regulation of glucose and lipid metabolism, melanocortin stimulating system suppression, or insulin sensitivity by magnesium chelation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34877366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34877366'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; weight gain and BMI increases ≥5% have been observed after 12 weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35233432','lexi-content-ref-31606734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35233432','lexi-content-ref-31606734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34888395','lexi-content-ref-32099991','lexi-content-ref-31339677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34888395','lexi-content-ref-32099991','lexi-content-ref-31339677'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Black or Hispanic race (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35130714','lexi-content-ref-HHS.2022','lexi-content-ref-32099991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35130714','lexi-content-ref-HHS.2022','lexi-content-ref-32099991'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32099991']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32099991'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pre-treatment obesity (adolescents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower pre-treatment BMI (adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022.1'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F51114134"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Hepatic: Increased serum bilirubin (17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Increased serum creatine kinase (6% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased LDL cholesterol (4% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (1% to 2%), abdominal pain (&lt;2%), diarrhea (3% to 6%), dyspepsia (&lt;2%), flatulence (&lt;2%), increased serum amylase (3%), increased serum lipase (≤2%), nausea (3% to 6%), vomiting (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased neutrophils (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase (1% to 2%), increased serum alanine aminotransferase (2% to 3%), increased serum aspartate aminotransferase (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (≤3%), depression (&lt;2%), dizziness (2%), fatigue (2% to 3%), headache (4% to 5%), insomnia (2%), suicidal ideation (2%), suicidal tendencies (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria (Sax 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dyslipidemia (Hwang 2023, Martini 2022, Moschopoulos 2023), gynecomastia (Biagi 2020), weight gain (Orkin 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (Simeni Njonnou 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Reactivation of HBV (following discontinuation in coinfected HIV-1 and HBV patients)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Simeni Njonnou 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Ueaphongsukkit 2021), Fanconi syndrome (Bahr 2019), proximal tubular nephropathy (Ueaphongsukkit 2021), renal tubular necrosis</p></div>
<div class="block coi drugH1Div" id="F51090586"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Coadministration with dofetilide, rifampin</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to bictegravir, emtricitabine , tenofovir alafenamide, or any component of the formulation; coadministration with St John’s wort</p></div>
<div class="block war drugH1Div" id="F51113144"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome, resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome, autoimmune hepatitis) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with the use of nucleoside analogs, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (marked transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in hepatic impairment; see "Dosing: Hepatic Impairment" for additional information.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in renal impairment; see "Dosing: Altered Kidney Function" for additional information.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53334591"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Emtricitabine-associated hyperpigmentation may occur at a higher frequency in pediatric patients compared to adults (children: 32%; adults: 2% to 6%).</p>
<p style="text-indent:-2em;margin-left:2em;">Through disruption in vitamin D metabolism, decreases in bone mineral density (BMD) have been observed with tenofovir alafenamide (TAF) after 48 weeks of treatment; however, the incidence and negative impact on BMD is less than that observed with tenofovir disoproxil fumarate (TDF). Due to potential adverse reactions, TAF is preferred over TDF whenever possible; do not use TAF and TDF concomitantly (HHS [pediatric] 2021).</p></div>
<div class="block foc drugH1Div" id="F51128448"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biktarvy: Bictegravir 30 mg, emtricitabine 120 mg, and tenofovir alafenamide 15 mg, Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg</p></div>
<div class="block geq drugH1Div" id="F51128446"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F51131769"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Biktarvy Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30-120-15 mg (per each): $159.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50-200-25 mg (per each): $159.25</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872364"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Biktarvy: Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg</p></div>
<div class="block admp drugH1Div" id="F53334590"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with or without food.</p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablet (pediatric patients weighing 14 to &lt;25 kg): If unable to swallow tablet whole, tablet may be split and each part swallowed separately; all parts should be swallowed within ~10 minutes.</p></div>
<div class="block adm drugH1Div" id="F51113285"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food. Administer 2 hours before or 6 hours after aluminum- or magnesium-containing antacids. Administer with food with concomitant calcium- or iron-containing supplements or antacids; coadministration with or 2 hours after calcium- or iron-containing supplements or antacids is <b>not</b> recommended under fasting conditions.</p>
<p style="text-indent:-2em;margin-left:2em;">Limited data are available for administration of crushed or dissolved tablets. A bioavailability study demonstrated that administration of crushed tablets may result in decreased emtricitabine and tenofovir alafenamide exposure, while administration of tablets dissolved in water may provide acceptable drug exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322475']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322475'])">Ref</a></span>). Clinical experience with administration of crushed or dissolved tablets is mixed; some case reports have demonstrated decreased efficacy (eg, development of resistance, increased viral load, virologic failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31982483','lexi-content-ref-35511892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31982483','lexi-content-ref-35511892'])">Ref</a></span>), while others have demonstrated successful virologic suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32862660','lexi-content-ref-32207818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32862660','lexi-content-ref-32207818'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F51113192"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Blister pack: Store at 25°C (77°F); excursion permitted to 15°C to 30°C (59°F to 86°F); store in original blister package.</p>
<p style="text-indent:-2em;margin-left:2em;">Bottle: Store below 30°C (86°F); dispense in original container. Do not discard desiccant.</p></div>
<div class="block usep drugH1Div" id="F53571449"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of HIV-1 infection as initial therapy in those with no antiretroviral (ARV) treatment history or to replace a current stable ARV regimen in those who are virologically suppressed (HIV-1 RNA &lt;50 copies/mL) with no history of treatment failure and no known substitutions associated with resistance to the individual components (FDA approved in pediatric patients weighing ≥14 kg and adults).</p></div>
<div class="block cyt drugH1Div" id="F51114998"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F51114995"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acyclovir-Valacyclovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adefovir: May diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Bictegravir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of Bictegravir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a calcium salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cidofovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OCT2 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Tenofovir Alafenamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Bictegravir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dalfampridine: OCT2 Inhibitors may increase the serum concentration of Dalfampridine.  Management: Consider alternatives to this combination. Carefully weigh the risk of seizures against the benefit of combining OCT2 inhibitors with dalfampridine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: Bictegravir may increase the serum concentration of Dofetilide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: Tenofovir Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: May decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron preparations under fed conditions, but coadministration with or 2 hours after an iron preparation is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates (High risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetFORMIN: MATE1/2-K Inhibitors may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May decrease the serum concentration of UGT1A1 Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Tenofovir Alafenamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible. Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose due to a potential risk of acute renal failure. Diclofenac appears to confer the most risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the nephrotoxic effect of Tenofovir Products.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Tenofovir Alafenamide. Management: Consider alternatives to the use of P-gp inducers with tenofovir alafenamide. If combined, monitor for reduced tenofovir alafenamide concentrations and efficacy, and for the development of resistance.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Bictegravir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Bictegravir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Bictegravir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of Tenofovir Alafenamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Bictegravir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Tenofovir Products may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Tenofovir Alafenamide.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">UGT1A1 Inducers: May decrease the serum concentration of Bictegravir.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F52914416"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Based on bictegravir, the Health and Human Services (HHS) perinatal HIV guidelines note data are insufficient to recommend this fixed-dose combination for patients with HIV who are not yet pregnant but are trying to conceive.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to the emtricitabine and tenofovir alafenamide monographs for additional information.</p></div>
<div class="block pri drugH1Div" id="F51113139"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Bictegravir crosses the placenta.</p>
<p style="text-indent:0em;">Data collected by the antiretroviral registry related to the use of bictegravir in pregnancy are insufficient to evaluate teratogenicity. Refer to the emtricitabine and tenofovir alafenamide monographs for additional information specific to these components.</p>
<p style="text-indent:0em;margin-top:2em;">Based on bictegravir, the Health and Human Services (HHS) perinatal HIV guidelines note data are insufficient to recommend this fixed-dose combination for pregnant patients with HIV infection who are antiretroviral naïve, who have had antiretroviral therapy (ART) in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). Patients who become pregnant during therapy may continue with frequent monitoring if viral suppression is effective and the regimen is well tolerated or consider changing to a preferred or alternate regimen due to insufficient data for bictegravir.</p>
<p style="text-indent:0em;margin-top:2em;">Pharmacokinetic studies of bictegravir are insufficient to make dosing recommendations for patients who are pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Refer to the emtricitabine and tenofovir alafenamide monographs for additional information.</p></div>
<div class="block mopp drugH1Div" id="F53571451"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">HIV: General recommendations: Management of HIV infection requires extensive monitoring; refer to current guidelines (<a href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=121790" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines</a>) for additional guidance. Antiretroviral (ARV) drug-resistance testing is recommended before initiation of therapy in treatment-naive patients. After initiation of or change in ARV therapy regimen, pediatric patients should be evaluated for clinical adverse effects and treatment adherence at 1 to 2 weeks, and laboratory testing for drug toxicity should occur at 2 to 4 weeks; monitor for therapy adherence, effectiveness, and toxicities every 3 to 4 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Drug-specific monitoring: Frequency may vary based on several factors including age, concomitant therapy, and clinical response; refer to current guidelines for additional information.</p>
<p style="text-indent:-2em;margin-left:4em;">Screen for hepatitis B prior to starting therapy (in patients who previously demonstrated no immunity to hepatitis B). For patients with hepatitis B coinfection, monitor hepatic function and hepatitis B viral load for several months after therapy is stopped.</p>
<p style="text-indent:-2em;margin-left:4em;">Serum electrolytes (including anion gap), SCr, serum phosphorus, urine protein/glucose, lipid profiles, bilirubin, creatine kinase (baseline and periodically with therapy or if clinical presentation indicates need), serum lactate (if clinical presentation indicates need).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Bictegravir may increase SCr via inhibition of tubular secretion; it does not affect glomerular filtration.</p></div>
<div class="block pha drugH1Div" id="F51113201"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bictegravir, an integrase inhibitor, inhibits HIV integrase by binding to the integrase-active site and blocking the strand transfer step of DNA integration. Emtricitabine is a cytidine analogue and tenofovir alafenamide is converted intracellularly to tenofovir (adenosine nucleotide analog) and subsequently phosphorylated by cellular kinases to the active moiety, tenofovir diphosphate. Emtricitabine and tenofovir alafenamide interfere with HIV viral RNA-dependent DNA polymerase activities resulting in inhibition of viral replication.</p></div>
<div class="block phk drugH1Div" id="F51113217"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Bictegravir: &gt;99%; Emtricitabine &lt;4%; Tenofovir alafenamide ~80%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism:</p>
<p style="text-indent:-2em;margin-left:4em;">Bictegravir: By CYP3A enzymes and hepatic glucuronidation mediated by UGT1A1</p>
<p style="text-indent:-2em;margin-left:4em;">Emtricitabine: Not significantly metabolized</p>
<p style="text-indent:-2em;margin-left:4em;">Tenofovir alafenamide: Converted intracellulary by hydrolysis (non-CYP enzymes) to tenofovir then phosphorylated by cellular kinases to the active moiety, tenofovir diphosphate; minimal extent by CYP3A</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Bictegravir: 17.3 hours; Emtricitabine: 10.4 hours; Tenofovir alafenamide: 0.51 hours (active metabolite, tenofovir diphosphate: 150 to 180 hours [intracellular])</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Bictegravir: 2 to 4 hours; Emtricitabine: 1.5 to 2 hours; Tenofovir alafenamide: 0.5 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Bictegravir: Feces (60.3%), urine (35%); Emtricitabine: Feces (13.7%), urine (70%); Tenofovir alafenamide: Feces (31.7%), urine (&lt;1%)</p></div>
<div class="block phksp drugH1Div" id="F56373476"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Exposures to all three components were higher in pediatric patients 3 to &lt;12 years of age as compared to adults and trough concentrations of bictegravir were lower in pediatric patients 12 to &lt;18 years as compared to adults; differences are not considered clinically significant.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27438578">
<a name="27438578"></a>Aloy B, Tazi I, Bagnis CI, et al. Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys? <i>AIDS Rev</i>. 2016;18(4):184-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/27438578/pubmed" id="27438578" target="_blank">27438578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34877881">
<a name="34877881"></a>Asundi A, Olson A, Jiang W, et al. Integrase inhibitor use associated with weight gain in women and incident diabetes mellitus. <i>AIDS Res Hum Retroviruses</i>. 2022;38(3):208-215. doi:10.1089/AID.2021.0091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/34877881/pubmed" id="34877881" target="_blank">34877881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30690644">
<a name="30690644"></a>Bahr NC, Yarlagadda SG. Fanconi syndrome and tenofovir alafenamide: A case report. <i>Ann Intern Med</i>. 2019;170(11):814-815. doi:10.7326/L18-0592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/30690644/pubmed" id="30690644" target="_blank">30690644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32041480">
<a name="32041480"></a>Biagi MJ, Schriever CA, Chiampas TD, Michienzi SM, Patel MC, Young JD, Badowski ME. Development of gynecomastia following initiation of bictegravir/emtricitabine/tenofovir alafenamide.<i> Int J STD AIDS</i>. 2020;31(4):380-382. doi:10.1177/0956462419895665<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32041480/pubmed" id="32041480" target="_blank">32041480</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences; October 2022.</div>
</li>
<li>
<div class="reference">
                  Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Biktarvy.3">
<a name="Biktarvy.3"></a>Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) [product monograph]. Mississauga, Ontario, Canada: Gilead Sciences Canada Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32868494">
<a name="32868494"></a>Cho AY, Oh JH, Moon HC, et al. A severe case of tenofovir-associated acute kidney injury requiring hemodialysis in a patient with chronic hepatitis B. <i>Kidney Res Clin Pract</i>. 2020;39(3):373-375. doi:10.23876/j.krcp.20.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32868494/pubmed" id="32868494" target="_blank">32868494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35017362">
<a name="35017362"></a>Deiva A, Jayaprakash V, Jose N, Chandan Kumar KN, Jayakumar M. Acute kidney injury in a patient treated with tenofovir alafenamide fumarate for Hepatitis B virus infection. <i>Saudi J Kidney Dis Transpl</i>. 2021;32(2):592-594. doi:10.4103/1319-2442.335480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/35017362/pubmed" id="35017362" target="_blank">35017362</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35233432">
<a name="35233432"></a>Emond B, Rossi C, Rogers R, Lefebvre P, Lafeuille MH, Donga P. Real-world analysis of weight gain and body mass index increase among patients with HIV-1 using antiretroviral regimen containing tenofovir alafenamide, tenofovir disoproxil fumarate, or neither in the United States. <i>J Health Econ Outcomes Res</i>. 2022;9(1):39-49. doi:10.36469/jheor.2022.31825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/35233432/pubmed" id="35233432" target="_blank">35233432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32862660">
<a name="32862660"></a>Ferrández JS, García AL, Alonso-Vega GG, González AO, García TM. Successful bictegravir/emtricitabine/tenofovir alafenamide treatment in a HIV patient with swallowing difficulties. <i>Ann Pharmacother</i>. 2021;55(4):556-557. doi:10.1177/1060028020953631<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32862660/pubmed" id="32862660" target="_blank">32862660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32207818">
<a name="32207818"></a>Fulco PP. Crushed bictegravir/emtricitabine/tenofovir alafenamide in a human immunodeficiency virus-positive patient with esophageal cancer. <i>Am J Health Syst Pharm</i>. 2020;77(7):509-510. doi:10.1093/ajhp/zxaa017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32207818/pubmed" id="32207818" target="_blank">32207818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27765666">
<a name="27765666"></a>Gaur AH, Kizito H, Prasitsueubsai W, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. <i>Lancet HIV</i>. 2016;3(12):e561-e568. doi:10.1016/S2352-3018(16)30121-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/27765666/pubmed" id="27765666" target="_blank">27765666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33626965">
<a name="33626965"></a>Goldberg RN, Kania AT, Michienzi SM, Patel M, Badowski ME. Weight gain in incarcerated individuals living with HIV after switching to integrase strand inhibitor-based therapy. <i>J Int Assoc Provid AIDS Care</i>. 2021;20:2325958221996860. doi:10.1177/2325958221996860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/33626965/pubmed" id="33626965" target="_blank">33626965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30269210">
<a name="30269210"></a>Gomez M, Seybold U, Roider J, Härter G, Bogner JR. A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. <i>Infection</i>. 2019;47(1):95-102. doi:10.1007/s15010-018-1227-0. Erratum in: <i>Infection</i>. 2018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/30269210/pubmed" id="30269210" target="_blank">30269210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31679186">
<a name="31679186"></a>Hamzah L, Williams D, Bailey AC, et al; Fanconi-Tenofovir Alafenamide trial team. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial. <i>HIV Med</i>. 2020;21(3):198-203. doi:10.1111/hiv.12819<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/31679186/pubmed" id="31679186" target="_blank">31679186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20811330">
<a name="20811330"></a>Herlitz LC, Mohan S, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. <i>Kidney Int</i>. 2010;78(11):1171-1177. doi:10.1038/ki.2010.318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/20811330/pubmed" id="20811330" target="_blank">20811330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32787843">
<a name="32787843"></a>Heron JE, Bloch M, Vanguru V, Saunders J, Gracey DM. Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report. <i>BMC Nephrol</i>. 2020;21(1):339. doi:10.1186/s12882-020-01981-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32787843/pubmed" id="32787843" target="_blank">32787843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35130714">
<a name="35130714"></a>Hester EK, Greenlee S, Durham SH. Weight changes with integrase strand transfer inhibitor therapy in the management of HIV infection: A systematic review. <i>Ann Pharmacother</i>. 2022 Feb 8:10600280211073321. doi:10.1177/10600280211073321<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/35130714/pubmed" id="35130714" target="_blank">35130714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>HHS. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new</a>. Updated April 11, 2023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/HHS.1/pubmed" id="HHS.1" target="_blank">HHS.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322475">
<a name="36322475"></a>Hocqueloux L, Lefeuvre S, Bois J, et al. Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study. <i>J Antimicrob Chemother</i>. 2022;78(1):161-168. doi:10.1093/jac/dkac369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/36322475/pubmed" id="36322475" target="_blank">36322475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37099248">
<a name="37099248"></a>Hwang EG, Jung EA, Yoo JJ, Kim SG, Kim YS. Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis. <i>Hepatol Int</i>. 2023;17(4):860-869. doi:10.1007/s12072-023-10528-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/37099248/pubmed" id="37099248" target="_blank">37099248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32985122">
<a name="32985122"></a>Ibrahim F, Samarawickrama A, Hamzah L, et al; BESTT Trial Team. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG. <i>HIV Med</i>. 2021;22(2):83-91. doi:10.1111/hiv.12961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32985122/pubmed" id="32985122" target="_blank">32985122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28403627">
<a name="28403627"></a>Karris MY. Short communication: Resolution of tenofovir disoproxil fumarate induced fanconi syndrome with switch to tenofovir alafenamide fumarate in a HIV-1 and hepatitis B coinfected patient. <i>AIDS Res Hum Retroviruses</i>. 2017;33(7):718-722. doi:10.1089/AID.2016.0180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/28403627/pubmed" id="28403627" target="_blank">28403627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31504324">
<a name="31504324"></a>Kerchberger AM, Sheth AN, Angert CD, et al. Weight gain associated with integrase stand transfer inhibitor use in women. <i>Clin Infect Dis</i>. 2020;71(3):593-600. doi:10.1093/cid/ciz853<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/31504324/pubmed" id="31504324" target="_blank">31504324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34888395">
<a name="34888395"></a>Kileel EM, Lo J, Malvestutto C, et al. Assessment of obesity and cardiometabolic status by integrase inhibitor use in REPRIEVE: A propensity-weighted analysis of a multinational primary cardiovascular prevention cohort of people with human immunodeficiency virus. <i>Open Forum Infect Dis</i>. 2021;8(12):ofab537. doi:10.1093/ofid/ofab537<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/34888395/pubmed" id="34888395" target="_blank">34888395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33633036">
<a name="33633036"></a>Kumar P, Johnson M, Molina JM, et al; DRIVE-SHIFT Study Group. Brief report: Switching to DOR/3TC/TDF maintains HIV-1 virologic suppression through week 144 in the DRIVE-SHIFT trial. <i>J Acquir Immune Defic Syndr</i>. 2021;87(2):801-805. doi:10.1097/QAI.0000000000002642<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/33633036/pubmed" id="33633036" target="_blank">33633036</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32099991">
<a name="32099991"></a>Lake JE, Wu K, Bares SH, et al. Risk factors for weight gain following switch to integrase inhibitor-based antiretroviral therapy. <i>Clin Infect Dis</i>. 2020;71(9):e471-e477. doi:10.1093/cid/ciaa177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32099991/pubmed" id="32099991" target="_blank">32099991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31982483">
<a name="31982483"></a>Lozano AB, Chueca N, de Salazar A, et al. Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient. <i>Antiviral Res</i>. 2020;179:104717. doi:10.1016/j.antiviral.2020.104717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/31982483/pubmed" id="31982483" target="_blank">31982483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36551920">
<a name="36551920"></a>Martini S, Maggi P, Gervasoni C, et al. Dynamics of lipid profile in antiretroviral-naïve HIV-infected patients, treated with TAF-based regimens: a multicenter observational study. <i>Biomedicines</i>. 2022;10(12):3164. doi:10.3390/biomedicines10123164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/36551920/pubmed" id="36551920" target="_blank">36551920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33176608">
<a name="33176608"></a>Max B, DeMarais P. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide discontinuation and return to normal weight. <i>Int J STD AIDS</i>. 2021;32(1):92-95. doi:10.1177/0956462420964341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/33176608/pubmed" id="33176608" target="_blank">33176608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36401506">
<a name="36401506"></a>Moschopoulos CD, Protopapas K, Thomas K, Kavatha D, Papadopoulos A, Antoniadou A. Switching from tenofovir disoproxil to tenofovir alafenamide fumarate: impact on cardiovascular risk and lipid profile in people living with HIV, an observational study. <i>AIDS Res Hum Retroviruses</i>. 2023;39(2):68-75. doi:10.1089/AID.2022.0086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/36401506/pubmed" id="36401506" target="_blank">36401506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30224952">
<a name="30224952"></a>Mothobi NZ, Masters J, Marriott DJ. Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient. <i>Ther Adv Infect Dis</i>. 2018;5(5):91-95. doi:10.1177/2049936118785497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/30224952/pubmed" id="30224952" target="_blank">30224952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35688166">
<a name="35688166"></a>Neesgaard B, Greenberg L, Miró JM, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. <i>Lancet HIV</i>. 2022;9(7):e474-e485. doi:10.1016/S2352-3018(22)00094-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/35688166/pubmed" id="35688166" target="_blank">35688166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28825943">
<a name="28825943"></a>Norwood J, Turner M, Bofill C, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. <i>J Acquir Immune Defic Syndr</i>. 2017;76(5):527-531. doi:10.1097/QAI.0000000000001525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/28825943/pubmed" id="28825943" target="_blank">28825943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28885375">
<a name="28885375"></a>Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, Atta MG. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report. <i>Medicine (Baltimore)</i>. 2017;96(36):e8046. doi:10.1097/MD.0000000000008046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/28885375/pubmed" id="28885375" target="_blank">28885375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32504574">
<a name="32504574"></a>Orkin C, DeJesus E, Sax PE, et al; GS-US-380-1489; GS-US-380-1490 study investigators. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. <i>Lancet HIV</i>. 2020;7(6):e389-e400. doi:10.1016/S2352-3018(20)30099-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32504574/pubmed" id="32504574" target="_blank">32504574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32796211">
<a name="32796211"></a>Pencolé L, Lê MP, Bouchet-Crivat F, Duro D, Peytavin G, Mandelbrot L. Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model. <i>AIDS</i>. 2020;34(14):2145-2149. doi:10.1097/QAD.0000000000002637<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32796211/pubmed" id="32796211" target="_blank">32796211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33048869">
<a name="33048869"></a>Pilkington V, Hughes SL, Pepperrell T, McCann K, Gotham D, Pozniak AL, Hill A. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. <i>AIDS</i>. 2020;34(15):2259-2268. doi:10.1097/QAD.0000000000002699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/33048869/pubmed" id="33048869" target="_blank">33048869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-:27673443">
<a name=":27673443"></a>Post FA, Tebas P, Clarke A, et al. Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in hiv-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. <i>J Acquir Immune Defic Syndr.</i> 2017;74(2):180-184. doi:10.1097/QAI.0000000000001186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/:27673443/pubmed" id=":27673443" target="_blank">:27673443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26627107">
<a name="26627107"></a>Pozniak A, Arribas JR, Gathe J, et al; GS-US-292-0112 Study Team. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. <i>J Acquir Immune Defic Syndr</i>. 2016;71(5):530-537. doi:10.1097/QAI.0000000000000908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/26627107/pubmed" id="26627107" target="_blank">26627107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32936919">
<a name="32936919"></a>Rebeiro PF, Jenkins CA, Bian A, et al. Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada. <i>Clin Infect Dis</i>. 2021;73(7):e2234-e2242. doi:10.1093/cid/ciaa1403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32936919/pubmed" id="32936919" target="_blank">32936919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35511892">
<a name="35511892"></a>Rowe SM, Clary JC, Drummond M, Derrick C, Sanasi K, Bookstaver PB. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: a case report and review of the literature. <i>Am J Health Syst Pharm</i>. 2022;79(16):1330-1336. doi:i10.1093/ajhp/zxac120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/35511892/pubmed" id="35511892" target="_blank">35511892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33148997">
<a name="33148997"></a>Ruderman SA, Crane HM, Nance RM, et al. Brief report: Weight gain following ART initiation in ART-naïve people living with HIV in the current treatment era. <i>J Acquir Immune Defic Syndr</i>. 2021;86(3):339-343. doi:10.1097/QAI.0000000000002556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/33148997/pubmed" id="33148997" target="_blank">33148997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28219610">
<a name="28219610"></a>Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. <i>Lancet HIV</i>. 2017a;4(4):e154-e160. doi:10.1016/S2352-3018(17)30016-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/28219610/pubmed" id="28219610" target="_blank">28219610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28867499">
<a name="28867499"></a>Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet</i>. 2017b;390(10107):2073-2082. doi:10.1016/S0140-6736(17)32340-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/28867499/pubmed" id="28867499" target="_blank">28867499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31606734">
<a name="31606734"></a>Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. <i>Clin Infect Dis</i>. 2020;71(6):1379-1389. doi:10.1093/cid/ciz999<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/31606734/pubmed" id="31606734" target="_blank">31606734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30151414">
<a name="30151414"></a>Serota DP, Franch HA, Cartwright EJ. Acute kidney injury in a patient on tenofovir alafenamide fumarate after initiation of treatment for hepatitis C virus infection. <i>Open Forum Infect Dis</i>. 2018;5(8):ofy189. doi:10.1093/ofid/ofy189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/30151414/pubmed" id="30151414" target="_blank">30151414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32611654">
<a name="32611654"></a>Simeni Njonnou SR, Henrard S, Noure L, Goffard JC. Severe rhabdomyolysis and acute asymptomatic pancreatitis following the concomitant use of Biktarvy in the setting of hyperosmolar diabetic crisis. <i>BMJ Case Rep</i>. 2020;13(7):e234483. doi:10.1136/bcr-2020-234483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/32611654/pubmed" id="32611654" target="_blank">32611654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31068272">
<a name="31068272"></a>Stellbrink HJ, Arribas JR, Stephens JL, et al. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet HIV</i>. 2019;6(6):e364-e372. doi:10.1016/S2352-3018(19)30080-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/31068272/pubmed" id="31068272" target="_blank">31068272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34419091">
<a name="34419091"></a>Ueaphongsukkit T, Gatechompol S, Avihingsanon A, et al. Tenofovir alafenamide nephrotoxicity: a case report and literature review. <i>AIDS Res Ther</i>. 2021;18(1):53. doi:10.1186/s12981-021-00380-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/34419091/pubmed" id="34419091" target="_blank">34419091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022">
<a name="HHS.2022"></a>US Department of Health and Human Services (HHS). Panel on Antiretroviral Guidelines for Adults and Adolescents. Updated March 23, 2023. Accessed May 16, 2023. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022.1">
<a name="HHS.2022.1"></a>US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in pediatric HIV infection. Updated April 11, 2022. Accessed August 29, 2022. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022.3">
<a name="HHS.2022.3"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new-guidelines</a>. Updated April 7, 2021. Accessed October 15, 2021.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24492366">
<a name="24492366"></a>Valade E, Tréluyer JM, Bouazza N, et al. Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. <i>Antimicrob Agents Chemother</i>. 2014;58(4):2256-2261. doi:10.1128/AAC.02058-13<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/24492366/pubmed" id="24492366" target="_blank">24492366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31905383">
<a name="31905383"></a>van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. <i>Clin Infect Dis</i>. 2020;71(8):1920-1929. doi:10.1093/cid/ciz1243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/31905383/pubmed" id="31905383" target="_blank">31905383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31339677">
<a name="31339677"></a>Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. <i>N Engl J Med</i>. 2019;381(9):803-815. doi:10.1056/NEJMoa1902824<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/31339677/pubmed" id="31339677" target="_blank">31339677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26251709">
<a name="26251709"></a>Waheed S, Attia D, Estrella MM, et al. Proximal tubular dysfunction and kidney injury associated with tenofovir in HIV patients: a case series. <i>Clin Kidney J</i>. 2015;8(4):420-425. doi:10.1093/ckj/sfv041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/26251709/pubmed" id="26251709" target="_blank">26251709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31068270">
<a name="31068270"></a>Wohl DA, Yazdanpanah Y, Baumgarten A, et al. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. <i>Lancet HIV</i>. 2019;6(6):e355-e363. doi:10.1016/S2352-3018(19)30077-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/31068270/pubmed" id="31068270" target="_blank">31068270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34877366">
<a name="34877366"></a>Wood BR, Huhn GD. Excess weight gain with integrase inhibitors and tenofovir alafenamide: What is the mechanism and does it matter? <i>Open Forum Infect Dis</i>. 2021;8(12):ofab542. doi:10.1093/ofid/ofab542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bictegravir-emtricitabine-and-tenofovir-alafenamide-pediatric-drug-information/abstract-text/34877366/pubmed" id="34877366" target="_blank">34877366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zhao.2018">
<a name="Zhao.2018"></a>Zhao X, Snachez CR, Gampa A, Rodby RA. Tenofovir alefanamide-induced nephrotoxicity: a rare case of fanconi syndrome and nephrogenic insipidus instigated by the "non-nephrotoxic" tenofovir-containing haart. <i>AJKD</i>; 2018:71(4):339.</div>
</li></ol></div><div id="topicVersionRevision">Topic 121790 Version 108.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
